146 related articles for article (PubMed ID: 17070825)
1. Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography.
Dhananjeyan MR; Liu J; Bykowski C; Trendel JA; Sarver JG; Ando H; Erhardt PW
J Chromatogr A; 2007 Jan; 1138(1-2):101-8. PubMed ID: 17070825
[TBL] [Abstract][Full Text] [Related]
2. A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
Vainchtein LD; Rosing H; Schellens JH; Beijnen JH
Biomed Chromatogr; 2010 Apr; 24(4):374-86. PubMed ID: 19650151
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry.
Deng P; Ji C; Dai X; Zhong D; Ding L; Chen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 May; 989():71-9. PubMed ID: 25808944
[TBL] [Abstract][Full Text] [Related]
4. Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.
Deenen MJ; Rosing H; Hillebrand MJ; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jan; 913-914():30-40. PubMed ID: 23270936
[TBL] [Abstract][Full Text] [Related]
5. Validation of a simple assay for the quantification of the capecitabine metabolites 5'-DFCR and 5'-DFUR for drug monitoring in patients receiving outpatient chemotherapy.
Buchner P; Mihola E; Sahmanovic A; Steininger T; Dittrich C; Czejka M
Anticancer Res; 2013 Mar; 33(3):881-6. PubMed ID: 23482757
[TBL] [Abstract][Full Text] [Related]
6. Development of a UPLC-MS/MS Assay for the Quantitative Determination of Capecitabine, 5'-deoxy-5-fluorocytidine (5'-dFCR), 5'-deoxy-5-fluorouridine (5'-dFUR), 5'-fluorouracil (5-FU), and α-fluoro-β-alanine (FBAL).
Knikman JE; de Vries N; Rosing H; Cats A; Guchelaar HJ; Beijnen JH
Pharmazie; 2023 Aug; 78(8):107-112. PubMed ID: 37592424
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies.
Guichard SM; Mayer I; Jodrell DI
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Nov; 826(1-2):232-7. PubMed ID: 16198157
[TBL] [Abstract][Full Text] [Related]
8. Simple determination of capecitabine and its metabolites by liquid chromatography with ultraviolet detection in a single injection.
Zufía L; Aldaz A; Giráldez J
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Sep; 809(1):51-8. PubMed ID: 15282093
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous determination of vinclozolin and detection of its degradation products in mouse plasma, serum and urine, and from rabbit bile, by high-performance liquid chromatography.
Dhananjeyan MR; Erhardt PW; Corbitt C
J Chromatogr A; 2006 May; 1115(1-2):8-18. PubMed ID: 16540112
[TBL] [Abstract][Full Text] [Related]
10. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
Tabata T; Katoh M; Tokudome S; Hosakawa M; Chiba K; Nakajima M; Yokoi T
Drug Metab Dispos; 2004 Jul; 32(7):762-7. PubMed ID: 15205393
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of a new anticancer drug galocitabine and its metabolites in blood by high-performance liquid chromatography.
Funaki T; Onodera H; Ogawa K; Ichihara S; Fukazawa H; Kuruma I
J Pharm Biomed Anal; 1993; 11(4-5):379-84. PubMed ID: 8357875
[TBL] [Abstract][Full Text] [Related]
12. Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens.
Farkouh A; Schueller J; Scheithauer W; Czejka M
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):487-8. PubMed ID: 20557855
[No Abstract] [Full Text] [Related]
13. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
Reigner B; Verweij J; Dirix L; Cassidy J; Twelves C; Allman D; Weidekamm E; Roos B; Banken L; Utoh M; Osterwalder B
Clin Cancer Res; 1998 Apr; 4(4):941-8. PubMed ID: 9563888
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous determination of capecitabine and its metabolite 5-fluorouracil by column switching and liquid chromatographic/tandem mass spectrometry.
Siethoff C; Orth M; Ortling A; Brendel E; Wagner-Redeker W
J Mass Spectrom; 2004 Aug; 39(8):884-9. PubMed ID: 15329840
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Urien S; Rezaí K; Lokiec F
J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):817-33. PubMed ID: 16284918
[TBL] [Abstract][Full Text] [Related]
16. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients.
Poole C; Gardiner J; Twelves C; Johnston P; Harper P; Cassidy J; Monkhouse J; Banken L; Weidekamm E; Reigner B
Cancer Chemother Pharmacol; 2002 Mar; 49(3):225-34. PubMed ID: 11935215
[TBL] [Abstract][Full Text] [Related]
17. Relationship between AUC of 5'-DFUR and toxicity of capecitabine, fluoropyrimidine carbamate analogs, and 5'-DFUR in monkeys, mice, and rats.
Shindoh H; Kawashima A; Shishido N; Nakano K; Kobayashi K; Horii I
J Toxicol Sci; 2006 Aug; 31(3):265-85. PubMed ID: 16960436
[TBL] [Abstract][Full Text] [Related]
18. Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma.
Xu Y; Grem JL
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jan; 783(1):273-85. PubMed ID: 12450548
[TBL] [Abstract][Full Text] [Related]
19. Isolation of an unknown metabolite of capecitabine, an oral 5-fluorouracil prodrug, and its identification by nuclear magnetic resonance and liquid chromatography-tandem mass spectrometry as a glucuroconjugate of 5'-deoxy-5-fluorocytidine, namely 2'-(beta-D-glucuronic acid)-5'-deoxy-5-fluorocytidine.
Desmoulin F; Gilard V; Martino R; Malet-Martino M
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jul; 792(2):323-32. PubMed ID: 12860040
[TBL] [Abstract][Full Text] [Related]
20. Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats.
Kobuchi S; Yazaki Y; Ito Y; Sakaeda T
Eur J Pharm Sci; 2018 Jan; 112():152-158. PubMed ID: 29175408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
